EP3300771B1 - Utilisation d'isosorbidecaprylates/caprates dans des déodorants et des anti-transpirants - Google Patents

Utilisation d'isosorbidecaprylates/caprates dans des déodorants et des anti-transpirants Download PDF

Info

Publication number
EP3300771B1
EP3300771B1 EP17196695.5A EP17196695A EP3300771B1 EP 3300771 B1 EP3300771 B1 EP 3300771B1 EP 17196695 A EP17196695 A EP 17196695A EP 3300771 B1 EP3300771 B1 EP 3300771B1
Authority
EP
European Patent Office
Prior art keywords
isosorbide
weight
sorbitan
composition
caprates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17196695.5A
Other languages
German (de)
English (en)
Other versions
EP3300771A1 (fr
Inventor
Tom Fricke
Peter Klug
Carina CHALUPPA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clariant International Ltd
Original Assignee
Clariant International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clariant International Ltd filed Critical Clariant International Ltd
Publication of EP3300771A1 publication Critical patent/EP3300771A1/fr
Application granted granted Critical
Publication of EP3300771B1 publication Critical patent/EP3300771B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants

Definitions

  • the present invention relates to the use of isosorbide caprylates / caprates in antiperspirants and deodorants to improve their effect on reducing body odor.
  • the object was therefore to provide compounds which improve the action of the antiperspirants and deodorants with regard to the duration of the reduction in body odor. They should also be based on renewable raw materials and should be toxicologically safe.
  • compositions comprising one or more isosorbide caprylates / caprates.
  • the invention thus relates to the use of a composition comprising one or more isosorbide caprylates / caprates (composition A) in antiperspirants and deodorants to improve their action to reduce body odor.
  • Isosorbide caprylates / caprates mean both the pure caprylates or caprates and also mixtures of caprylates and caprates.
  • the isosorbide caprylates / caprates are mixtures of caprylates and caprates, preferably in a molar ratio of 1: 2 to 2: 1 and particularly preferably in a molar ratio of 2: 3 to 3: 2.
  • the isosorbide caprylates / caprates are caprylates with a caprate fraction of at most 5 mol%, particularly preferably of at most 0.5 mol% and particularly preferably pure caprylates which are free of Caprates.
  • the isosorbide caprylates / caprates are caprates with a caprylate content of at most 5 mol%, particularly preferably of at most 0.5 mol% and particularly preferably pure caprates which are free of Caprylates.
  • Body odor is preferably understood to mean the smell of sweat.
  • compositions A contain, in addition to the one or more isosorbide caprylates / caprates, one or more sorbitan caprylates / caprates.
  • the sorbitan caprylates / caprates are mixtures of caprylates and caprates, preferably in a molar ratio of 1: 2 to 2: 1 and particularly preferably in a molar ratio of 2: 3 to 3: 2.
  • the sorbitan caprylates / caprates are caprylates with a proportion of the caprates of a maximum of 5 mol%, particularly preferably a maximum of 0.5 mol% and particularly preferably pure caprylates which are free of caprates.
  • the sorbitan caprylates / caprates are caprates with a caprylate content of at most 5 mol%, particularly preferably of at most 0.5 mol% and particularly preferably pure caprates which are free of Caprylates.
  • the isosorbide caprylates / caprates can be isosorbide monocaprylate / caprate, isosorbide dicaprylate / caprate or any mixtures thereof.
  • the sorbitan caprylates / caprates can be mono-, di-, tri- or tetracaprylate / caprate or any mixtures thereof.
  • Sorbitan caprylate / caprate and isosorbide caprylate / caprate are based on renewable raw materials and are toxicologically safe.
  • compositions such as isosorbide caprylates / caprates and / or sorbitan caprylates / caprates in compositions such. B. in cosmetic, dermatological or pharmaceutical compositions is already known.
  • WO 2010/108738 A2 (Evonik) describes formulations for the cleaning and care of human or animal parts of the body containing sorbitan carboxylic acid esters, the carboxylic acid portion of the sorbitan carboxylic acid ester being derived from a carboxylic acid containing 6 to 10 carbon atoms and the sorbitan carboxylic acid esters having a hydroxyl number (OH number) of greater than 350 and the use of Sorbitan carboxylic acid esters mentioned as viscosity regulators, care ingredients, foam boosters or solubilizers in cleaning or care formulations.
  • OH number hydroxyl number
  • JP 8173787 (A ) (Lion) describes a composition containing a surfactant containing a fatty acid ester of dehydrated sorbitol and the use as an oil-in-water emulsifier and as a cleaning base.
  • the compositions may contain mono- or diesters of caprylic and / or capric acid with a polyol selected from the group consisting of 1,5-sorbitan, 1,4-sorbitan and isosorbide.
  • Isosorbide caprylate / caprate and sorbitan caprylate / caprate can e.g. B. according to methods familiar to the skilled worker.
  • these compounds can be prepared by esterification of sorbitol or isosorbide by customary methods known to those skilled in the art, both sorbitol and isosorbide itself and the acid components used for the esterification in turn being commercially available.
  • the effect of the antiperspirants and deodorants is preferably further improved with regard to the duration of the reduction in body odor.
  • composition A preferably contains one or more further compounds selected from the group consisting of caprylic acid, capric acid, sorbitol, sorbitol caprylates, sorbitol caprates, sorbitan and isosorbide and optionally one or more sorbitan caprylates / caprates.
  • the sorbitol caprylates and sorbitol caprates can be the corresponding mono-, di-, tri-, tetra-, penta- and hexa esters of sorbitol or any mixtures of these substances.
  • composition A at least 50.0% by weight, preferably at least 60.0% by weight. %, particularly preferably at least 70.0% by weight and particularly preferably at least 75.0% by weight, based on the total weight of composition A.
  • Composition A further preferably contains isosorbide monocaprylate / caprate.
  • Composition A further preferably contains, in addition to isosorbide monocaprylate / caprate, additionally sorbitan monocaprylate / caprate.
  • the total amount of isosorbide monocaprylate / caprate and the sorbitan monocaprylate / caprate optionally additionally contained in composition A in composition A is at least 30.0% by weight, preferably at least 35.0% by weight, particularly preferably at least 40.0 % By weight and particularly preferably at least 45% by weight, based on the total weight of composition A.
  • the total amount of isosorbide monocaprylate / caprate and the sorbitan monocaprylate / caprate optionally additionally contained in composition A can be up to 100% by weight in composition A. -%.
  • the total amount of isosorbide monocaprylate / caprate and the sorbitan monocaprylate / caprate optionally additionally contained in composition A is only up to 90.0% by weight, preferably up to 80.0% by weight and particularly preferably up to 70.0% by weight.
  • composition A contains, in addition to isosorbide monocaprylate / caprate, sorbitan monocaprylate / caprate and the weight ratio of sorbitan monocaprylate / caprate to isosorbide monocaprylate / caprate in composition A is from 20: 1 to 1: 100, preferably from 10: 1 to 1:10, particularly preferably from 6: 1 to 1: 6, particularly preferably from 3: 1 to 1: 5 and extremely preferably from 1: 1 to 1: 4.
  • compositions A either contain no caprylic acid and capric acid or up to 1.0% by weight of caprylic acid and capric acid.
  • compositions A contain no compounds selected from sorbitol, sorbitol caprylates and sorbitol caprates.
  • compositions A consist of the one or more isosorbide caprylates / caprates, optionally additionally the one or more sorbitan caprylates / caprates and optionally additionally the one or more compounds selected from the group consisting of caprylic acid, capric acid, Sorbitol, sorbitol caprylates, sorbitol caprates, sorbitan and isosorbide.
  • compositions A contain one or more compounds selected from sorbitol, sorbitol caprylates and sorbitol caprates, these compounds are preferably together in an amount less than or equal to 5.0% by weight, particularly preferably in an amount less than or equal to 3.0% by weight. %, particularly preferably in an amount less than or equal to 1.0% by weight and extremely preferably in an amount less than or equal to 0.5% by weight in compositions A, the details in% by weight in each case referring to the Total weight of the finished compositions A are related.
  • the hydroxyl or OH number of a substance is understood to mean that amount of KOH in mg which is equivalent to the amount of acetic acid bound in the acetylation of 1 g of substance.
  • Suitable methods of determination for determining the OH number are e.g. B. DGF CV 17 a (53), Ph.Eur.2.5.3 Method A and DIN 53240 .
  • the OH numbers are determined based on DIN 53240-2.
  • the procedure is as follows: 1 g of the homogenized sample to be measured is weighed to the nearest 0.1 mg. 20.00 ml of acetylation mixture (acetylation mixture: 50 ml of acetic anhydride are stirred into 1 liter of pyridine) are added. The sample is completely dissolved in the acetylation mixture, if necessary with stirring and heating. 5 ml of catalyst solution (catalyst solution: 2 g of 4-dimethylaminopyridine are dissolved in 100 ml of pyridine) are added. The reaction vessel is closed and placed in the preheated water bath at 55 ° C for 10 minutes, mixing well.
  • reaction solution is then mixed with 10 ml of deionized water, the reaction vessel is closed again and allowed to react again in the shaking water bath for 10 minutes.
  • the sample is cooled to room temperature (25 ° C). 50 ml of 2-propanol and 2 drops of phenolphthalein are then added.
  • Vb - Va is the amount of the sodium hydroxide solution used in ml which is equivalent to the amount of acetic acid bound in the acetylation of the sample to be measured described above.
  • the amount of composition A in the antiperspirant or deodorant is preferably from 0.1 to 20.0% by weight, particularly preferably from 0.5 to 15.0% by weight, particularly preferably from 2.0 to 13.0 % By weight and extremely preferably from 3.0 to 10.0% by weight, based on the total weight of the antiperspirant or deodorant.
  • the antiperspirants and deodorants preferably contain no aluminum-containing compounds.
  • the antiperspirants and deodorants contain no further substances which are active against body odor.
  • further substances which are active against body odor are understood in particular to be compounds which differ from caprylic acid, capric acid, sorbitol, sorbitol caprylates, sorbitol caprates, sorbitan, sorbitan caprylates / caprates, isosorbide and isosorbide caprylates / caprates.
  • the antiperspirants and deodorants contain one or more further substances which are active against body odor.
  • the one or more further substances active against body odor are preferably selected from the group consisting of Acorus Gramineus Root / Stem / Luffa Cylindrica Fruit / Camellia Sinensis Leaf Extract, Adipic Acid / Neopentyl Glycol Crosspolymer, Alpinia Uraiensis Stalk / Leaf Water, Amber Powder , Ammonium Phenolsulfonate, Ammonium Silver Zeolite, Ammonium Silver Zinc Aluminum Silicate, Benzalkonium Bromide, Benzalkonium Cetyl Phosphate, Benzalkonium Chloride, Benzalkonium Saccharinate, Benzethonium Chloride, Boesenbergia Pandurata Rhizome Extract, Bromochlorophene, Bursera Graveolens Fruit Oil / Acrylate Acrylate Fruit Oil, Acrylate Acrylate Copolymer, t-Butyl Methylphenoxy Phenol, Butyloctanoic Acid
  • the one or more further substances active against body odor are particularly preferably selected from the group consisting of caprylyl glycol, chitosan, ethylhexylglycerol, glyceryl caprylate, glyceryl caprylate / caprate, octanediol, piroctonol, piroctone olamine, silver citrate, silver chloride (and) Titanium Dioxide, Silver Chloride (and) Titanium Dioxide (and) Diethylhexyl Sodium Sulfosuccinate (and) Propylene Glycol, Silver Lactate, Triclosan, Triethylcitrate and Zinc Ricinoleate.
  • the one or more further substances active against body odor are particularly preferably selected from the group consisting of zinc ricinoleates, silver chloride (and) titanium dioxide (and) diethylhexyl sodium sulfosuccinate (and) propylene glycol, piroctonol, piroctone olamine, chitosan, octanediol , Ethylhexylglycerol, caprylyl glycol, glyceryl caprylate, glyceryl caprylate / caprate, silver citrate, silver lactate, triclosan and triethyl citrate.
  • the one or more further substances active against body odor are selected with extreme preference from the group consisting of Zinc Ricinoleate, Silver Chloride (and) Titanium Dioxide (and) Diethylhexyl Sodium Sulfosuccinate (and) Propylene Glycol (e.g. JM ActiCare®) , Piroctonol, chitosan, octanediol and piroctone olamine.
  • the antiperspirants or deodorants are preferably in the form of sticks, roll-ons, fluids, gels, sprays, lotions or creams.
  • the antiperspirants or deodorants are preferably built up on an aqueous or aqueous-alcoholic basis or are in the form of emulsions or Dispersions. They are particularly preferably in the form of emulsions and particularly preferably they are in the form of oil-in-water emulsions.
  • the antiperspirants or deodorants can contain, as further auxiliaries and additives, all substances customarily used for this application, for example oils, waxes, emulsifiers, co-emulsifiers, dispersants, surfactants, defoamers, solubilizers, electrolytes, hydroxy acids, stabilizers, polymers, film formers, Thickeners, gelling agents, superfatting agents, refatting agents, other antimicrobial agents, biogenic agents, astringents, active agents, sun protection filters, antioxidants, oxidants, humectants, solvents, colorants, pigments, pearlescent agents, fragrances, opacifiers and / or silicones.
  • oils for example oils, waxes, emulsifiers, co-emulsifiers, dispersants, surfactants, defoamers, solubilizers, electrolytes, hydroxy acids, stabilizers, polymers, film formers, Thickeners, gelling agents, superfatting agents,
  • the antiperspirants or deodorants have pH values of preferably 2 to 11, particularly preferably 4.5 to 8.5 and particularly preferably 5.0 to 6.5.
  • phase ingredient % By weight A water ad 100 B Talc (Luzenac® 00) 9.0 C. Ammonium Acryloyldimethyltaurate / Beheneth-25 Methacrylate Crosspolymer (Aristoflex® HMB) 0.6 Xanthan gum 0.1 D Squalane 9.0 E Preservative q.s.
  • phase ingredient % By weight A water ad 100 B PEG-150 Distearate (Rewopal® PEG 6000 DS) 1.0 C. Ceteareth-25 (Genapol® T 250) 5.0 Butylene glycol 3.0 Dicaprylyl ether (Cetiol® OE) 1.0 Glyceryl isostearate 2.0 D water 15.0 Lactic acid q.s. E Preservative q.s.
  • the subjects' two axils are preconditioned over several days, i.e. H. no antiperspirants and deodorants are used and a pH-skin-neutral, unscented liquid soap is used.
  • the axillary body odor and product fragrance according to intensity before and after treatment for a total of 48 hours by three olfactory experts rated.
  • the opposite axilla is not treated and serves as a standard for determining the relative decrease in intensity of the axillary body odor in comparison to the axilla, which was treated with the basic formulation containing active substances against body odor in component D.
  • Tables A1-A6 Results of attempts to reduce body odor using sorbitan / isosorbide caprylate X1 after 24 and 48 hours composition added to basic formulation Basic wording Result after 24 hours [%] Result after 48 hours [%] no I. 0 0 7.6% by weight sorbitan / isosorbide caprylate X1 I. 23 21st no II 0 0 1.0% by weight sorbitan / isosorbide caprylate X1 II 10th 9 4.0% by weight sorbitan / isosorbide caprylate X1 II 21st 20th
  • Table A1 show that the ingredients of the basic formulation do not reduce body odor.
  • the addition of up to 7.6% by weight of sorbitan / isosorbide caprylate X1 reduces the intensity of the body odor over the examined period of 48 hours after application. What is striking here is that the reduction in the intensity of body odor is surprisingly 48 hours after application only slightly below the value 24 hours after application.
  • Table A2 Results of attempts to reduce body odor using sorbitan / isosorbide caprylate X1, octanediol, zinc ricinoleate and combination after 24 and 48 hours composition added to basic formulation I.
  • Table A3 show that sorbitan / isosorbide caprylate X1 in antiperspirants and deodorants improves the effect of JM ActiCare® in terms of the strength and duration of the reduction in body odor.
  • Table A4 Results of attempts to reduce body odor using sorbitan / isosorbide caprylate X1 and piroctonol after 24 and 48 hours composition added to basic formulation I.
  • Table A5 show that sorbitan / isosorbide caprylate X1 in antiperspirants and deodorants improves the effect of Zenvivo® Aqua in terms of the strength and duration of the reduction in body odor.
  • Table A6 Results from attempts to reduce body odor using sorbitan / isosorbide caprylate X1 and Zenvivo® Protect after 24 and 48 hours composition added to basic formulation II Result after 24 hours [%] Result after 48 hours [%] 0.4% by weight Zenvivo® Protect 28 19th 1.0% by weight sorbitan / isosorbide caprylate X1 + 0.4% by weight Zenvivo® Protect 32 25th
  • phase ingredient % By weight A Hydroxyethyl cellulose (Tylose® H 10000 G4) 0.7 B water ad 100 C. Piroctone Olamine (Octopirox®) 0.2 D Ethanol 30.0 E Sorbitan / isosorbide caprylate X1 8.0 Propylene glycol 5.0 PEG-40 Hydrogenated Castor Oil (Emulsogen® HCO 040) 0.5 F Citric Acid (pH 5.0-5.5) q.s.
  • phase ingredient % By weight A Piroctone Olamine (Octopirox®) 0.1 Sorbitan / isosorbide caprylate X1 4.0 1,3-butanediol 30.0 Propylene glycol 27.0 Isosteareth-20 (Rewoderm® 66E) 4.0 Steareth-2 (Genapol® HS 020) 1.0 B Polyglycol 1500 (PEG-32) 5.0 C. water ad 100 D Sodium stearate 6.0
  • phase ingredient % By weight A PEG-40 Hydrogenated Castor Oil (Emulsogen® HCO 040) 1.0 25.0 Ethanol 0.1 Piroctone Olamine (Octopirox®) 3.0 Sorbitan / isosorbide caprylate X1 B Propylene glycol 20.0 Diisopropyl Adipate (Isoadipate® 660014) 1.0 water ad 100 C. Citric acid q.s. D Ammonium Acryloyldimethyltaurate / VP Copolymer (Aristoflex® AVC) 1.3
  • Formulation example 4 Antiperspirant in the form of a foot spray
  • phase ingredient % By weight
  • B Ethanol 55.0 Propylene glycol 5.0
  • Formulation example 5 Deodorant in the form of a foot cream
  • phase ingredient % By weight A Piroctone Olamine (Octopirox®) 0.2 Propylene glycol 2.0 B Triceteareth-4 phosphates (Hostaphat® KW 340 D) 2.5 Sorbitan / isosorbide caprylate X1 5.0 Caprylyl Methicone (SilCare® Silicone 41M15) 1.0 PEG-4 polyglyceryl-2 stearate (Hostacerin® DGSB) 1.5 Cetearyl alcohol 2.0 Caprylic / Capric Triglyceride (Velsan® CCT) 4.0 C. Ammonium Acryloyldimethyltaurate / VP Copolymer (Aristoflex® AVC) 0.8 D water ad 100 Propylene glycol 2.0 E Camphor 0.1 menthol 0.2 F Citric acid q.s.
  • Zinc Ricinoleate, JM ActiCare®, Piroctonol, Chitosan (Zenvivo® Aqua, Zenvio® Protect), Octanediol, Ethylhexylglycerin, Caprylyl Glycol, Glyceryl Caprylate, Glyceryl Caprylate / Caprate can be used instead of Piroctone Olamine.
  • sorbitan / isosorbide caprylate X1 instead of sorbitan / isosorbide caprylate X1, it is also possible to use sorbitan / isosorbide caprylate X2, isosorbide caprylate X3, sorbitan / isosorbide caprate X4, sorbitan / isosorbide caprate X5, isosorbide caprate X6 / sorbitan capate / 7 / sorbitan cap / X Incorporate isosorbide caprylate / caprat X8 and isosorbide caprylate / caprat X9.
  • Sorbitan / isosorbide caprate X4 of the following composition:
  • Sorbitan / isosorbide caprylate / caprat X7 of the following composition:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)

Claims (15)

  1. Utilisation d'une composition contenant un ou plusieurs caprylates/caprates d'isosorbide (composition A) dans des antitranspirants et des déodorants pour l'amélioration de l'effet des antitranspirants et des déodorants en ce qui concerne la durée de l'atténuation de l'odeur corporelle.
  2. Utilisation selon la revendication 1, caractérisée en ce que la composition A contient de plus, outre le ou les caprylates/caprates d'isosorbide, un ou plusieurs caprylates/caprates de sorbitane.
  3. Utilisation selon la revendication 1 ou 2, caractérisée en ce que l'effet des antitranspirants et des déodorants en ce qui concerne le pouvoir d'atténuation de l'odeur corporelle étant amélioré.
  4. Utilisation selon l'une ou plusieurs des revendications 1 à 3, caractérisée en ce que la composition A contient, outre le ou les caprylates/caprates d'isosorbide, un ou plusieurs composés supplémentaires choisis dans le groupe constitué par l'acide caprylique, l'acide caprique, le sorbitol, des caprylates de sorbitol, des caprates de sorbitol, le sorbitane et l'isosorbide et éventuellement un ou plusieurs caprylates/caprates de sorbitane.
  5. Utilisation selon l'une ou plusieurs des revendications 1 à 4, caractérisée en ce que la quantité totale du ou des caprylates/caprates d'isosorbide et du ou des caprylates/caprates de sorbitane éventuellement de plus contenus dans la composition A, dans la composition A est d'au moins 50,0 % en poids, par rapport au poids total de la composition A.
  6. Utilisation selon l'une ou plusieurs des revendications 1 à 5, caractérisée en ce que la quantité totale du ou des caprylates/caprates d'isosorbide et du ou des caprylates/caprates de sorbitane éventuellement de plus contenus dans la composition A, dans la composition A est d'au moins 60,0 % en poids, particulièrement préférablement d'au moins 70,0 % en poids et en particulier préférablement d'au moins 75,0 % en poids, par rapport au poids total de la composition A.
  7. Utilisation selon l'une ou plusieurs des revendications 1 à 6, caractérisée en ce que la composition A contient du monocaprylate/caprate d'isosorbide.
  8. Utilisation selon la revendication 7, caractérisée en ce que la composition A contient de plus, outre le monocaprylate/caprate d'isosorbide, du monocaprylate/caprate de sorbitane.
  9. Utilisation selon la revendication 7 ou 8, caractérisée en ce que la quantité totale de monocaprylate/caprate d'isosorbide et du monocaprylate/caprate de sorbitane éventuellement de plus contenu dans la composition A, dans la composition A est d'au moins 30,0 % en poids, de préférence d'au moins 35,0 % en poids, particulièrement préférablement d'au moins 40,0 % en poids et en particulier préférablement d'au moins 45 % en poids, par rapport au poids total de la composition A.
  10. Utilisation selon la revendication 8 ou 9, caractérisée en ce que la composition A contient de plus, outre le monocaprylate/caprate d'isosorbide, du monocaprylate/caprate de sorbitane et le rapport pondéral de monocaprylate/caprate de sorbitane à monocaprylate/caprate d'isosorbide dans la composition A est de 20:1 à 1:100, de préférence de 10:1 à 1:10, particulièrement préférablement de 6:1 à 1:6, en particulier préférablement de 3:1 à 1:5 et extraordinairement préférablement de 1:1 à 1:4.
  11. Utilisation selon l'une ou plusieurs des revendications 1 à 10, caractérisée en ce que la quantité de composition A dans l'antitranspirant ou le déodorant est de 0,1 à 20,0 % en poids, de préférence de 0,5 à 15,0 % en poids, particulièrement préférablement de 2,0 à 13,0 % en poids et en particulier préférablement de 3,0 à 10,0 % en poids, par rapport au poids total de l'antitranspirant ou du déodorant.
  12. Utilisation selon l'une ou plusieurs des revendications 1 à 11, caractérisée en ce que les antitranspirants et les déodorants ne contiennent aucun composé contenant de l'aluminium.
  13. Utilisation selon l'une ou plusieurs des revendications 1 à 12, caractérisée en ce que les antitranspirants et les déodorants ne contiennent aucune substance active supplémentaire contre l'odeur corporelle.
  14. Utilisation selon l'une ou plusieurs des revendications 1 à 12, caractérisée en ce que les antitranspirants et les déodorants contiennent une ou plusieurs substances actives supplémentaires contre l'odeur corporelle.
  15. Utilisation selon la revendication 14, caractérisée en ce que la ou les substances actives supplémentaires contre l'odeur corporelle sont choisies dans le groupe constitué par le caprylyle glycol, le chitosane, l'éthylhexylglycérine, le caprylate de glycéryle, le caprylate/caprate de glycéryle, l'octanediol, le piroctonol, la piroctone-olamine, le citrate d'argent, le chlorure d'argent (et) les dioxydes de titane, le chlorure d'argent (et) les dioxydes de titane (et) le sulfosuccinate sodique de diéthylhexyle (et) le propylèneglycol, le lactate d'argent, le triclosan, le citrate de triéthyle et le ricinoléate de zinc.
EP17196695.5A 2011-11-22 2012-11-21 Utilisation d'isosorbidecaprylates/caprates dans des déodorants et des anti-transpirants Active EP3300771B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011119033A DE102011119033A1 (de) 2011-11-22 2011-11-22 Verwendung von Isosorbidcaprylaten/capraten in Deodorantien und Antiperspirantien
EP12798153.8A EP2782645B1 (fr) 2011-11-22 2012-11-21 Utilisation de caprylates/caprates d'isosorbide dans des déodorants et des anti-transpirants
PCT/EP2012/004827 WO2013075826A2 (fr) 2011-11-22 2012-11-21 Utilisation de caprylates/caprates d'isosorbide dans des déodorants et des anti-transpirants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP12798153.8A Division EP2782645B1 (fr) 2011-11-22 2012-11-21 Utilisation de caprylates/caprates d'isosorbide dans des déodorants et des anti-transpirants

Publications (2)

Publication Number Publication Date
EP3300771A1 EP3300771A1 (fr) 2018-04-04
EP3300771B1 true EP3300771B1 (fr) 2020-06-17

Family

ID=46671455

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17196695.5A Active EP3300771B1 (fr) 2011-11-22 2012-11-21 Utilisation d'isosorbidecaprylates/caprates dans des déodorants et des anti-transpirants
EP12798153.8A Active EP2782645B1 (fr) 2011-11-22 2012-11-21 Utilisation de caprylates/caprates d'isosorbide dans des déodorants et des anti-transpirants

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12798153.8A Active EP2782645B1 (fr) 2011-11-22 2012-11-21 Utilisation de caprylates/caprates d'isosorbide dans des déodorants et des anti-transpirants

Country Status (7)

Country Link
US (1) US20140322151A1 (fr)
EP (2) EP3300771B1 (fr)
JP (2) JP6236395B2 (fr)
CN (1) CN104302359B (fr)
BR (1) BR112014012246A2 (fr)
DE (1) DE102011119033A1 (fr)
WO (1) WO2013075826A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009022445A1 (de) 2009-05-23 2009-12-24 Clariant International Limited Zusammensetzung enthaltend Sorbitanmonocaprylat und Alkohol
WO2013017255A1 (fr) 2011-08-04 2013-02-07 Clariant International Ltd Utilisation de monoesters d'isosorbide en tant qu'epaississants
ES2562854T3 (es) 2011-08-04 2016-03-08 Clariant International Ltd Empleo de monoésteres de isosorbida como productos activos fungicidas
JP6037574B2 (ja) 2011-08-04 2016-12-07 クラリアント・インターナシヨナル・リミテツド イソソルビドモノエステルおよびｎ−ヒドロキシピリドン類を含有する組成物
WO2013017261A1 (fr) 2011-08-04 2013-02-07 Clariant International Ltd Composition contenant des monoesters d'isosorbide et des diesters d'isosorbide
JP6120845B2 (ja) 2011-08-04 2017-04-26 クラリアント・インターナシヨナル・リミテツド イソソルビドモノエステルと、少なくとも１個の芳香族基を含有するアルコールとを含有する組成物
DE102011119033A1 (de) * 2011-11-22 2012-09-06 Clariant International Ltd. Verwendung von Isosorbidcaprylaten/capraten in Deodorantien und Antiperspirantien
JP6339940B2 (ja) 2011-12-20 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド 真菌感染症の治療用の局所用オイル組成物
FR2998569B1 (fr) * 2012-11-26 2015-01-09 Roquette Freres Procede de fabrication de compositions de diesters de 1,4 : 3,6-dianhydrohexitol
WO2016090247A1 (fr) * 2014-12-05 2016-06-09 Mary Kay Inc. Compositions cosmétiques
ES2770111T3 (es) 2015-04-24 2020-06-30 Basf Se Diésteres de isosorbida como agentes nacarantes y opacificantes
US20180289003A1 (en) * 2015-08-24 2018-10-11 Smith & Nephew, Inc. Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms
DE102015225958A1 (de) * 2015-12-18 2017-06-22 Henkel Ag & Co. Kgaa Kosmetische Mittel, enthaltend eine Kombination von mindestens zwei verschiedenen Wirkstoffen
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
JP2019510036A (ja) 2016-03-31 2019-04-11 ゴジョ・インダストリーズ・インコーポレイテッド プロバイオティクス／プレバイオティクス有効成分を含む清浄剤組成物
GR1009087B (el) * 2016-06-01 2017-08-11 ΦΑΡΜΑΣΕΠΤ - ΕΙΣΑΓ - ΑΝΤΙΠΡΟΣΩΠΕΙΕΣ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΕΙΔΩΝ με δ.τ. "PHARMASEPT Ε.Π.Ε. Συστατικο για την παραγωγη καλλυντικων προϊοντων
EP3468544A2 (fr) * 2016-06-13 2019-04-17 Vyome Therapeutics Limited Compositions antifongiques synergiques et leurs procédés
WO2017216722A2 (fr) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Compositions antifongiques synergiques et leurs procédés
AU2017285148B2 (en) 2016-06-17 2019-05-16 Unilever Global Ip Limited Deodorant products
PL3538058T3 (pl) * 2016-11-10 2022-04-19 Givaudan Sa Środek dezodoryzujący zawierający neodekanian cynku
AU2017365019A1 (en) 2016-11-23 2019-07-11 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
JP7436386B2 (ja) 2018-12-04 2024-02-21 日清オイリオグループ株式会社 油性保湿剤及びそれを含む皮膚外用組成物
FR3108034B1 (fr) 2020-03-11 2022-09-09 Hyteck Composition deodorante

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2507425B2 (ja) * 1987-05-23 1996-06-12 新田ゼラチン株式会社 化粧料
IL112649A (en) * 1994-02-22 1999-12-22 Curtis Helene Ind Inc Topically effective compositions for application to the skin or hair
JPH08173787A (ja) 1994-08-12 1996-07-09 Lion Corp 界面活性剤組成物
JPH08187070A (ja) * 1994-11-10 1996-07-23 Lion Corp 飲食品用抗菌剤及び飲食品
JP3936968B2 (ja) * 2000-04-27 2007-06-27 塩野香料株式会社 天然物由来の抗菌剤、抗菌性香料および、それらを含有する化粧品
JP2002255774A (ja) * 2001-03-02 2002-09-11 Kao Corp デオドラント剤
DE102009001748A1 (de) 2009-03-23 2010-09-30 Evonik Goldschmidt Gmbh Formulierungen enthaltend Sorbitancarbonsäureester
DE102009022444A1 (de) 2009-05-23 2010-01-07 Clariant International Limited Zusammensetzung enthaltend Sorbitanmonocaprylat und antimikrobielle Wirkstoffe
DE102009022445A1 (de) 2009-05-23 2009-12-24 Clariant International Limited Zusammensetzung enthaltend Sorbitanmonocaprylat und Alkohol
EP2739148B1 (fr) * 2011-08-04 2016-09-28 Clariant International Ltd Compositions comprenant du monoester d'isosorbide et des diols aliphatiques vicinals
DE102011119033A1 (de) * 2011-11-22 2012-09-06 Clariant International Ltd. Verwendung von Isosorbidcaprylaten/capraten in Deodorantien und Antiperspirantien

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2013075826A2 (fr) 2013-05-30
EP2782645B1 (fr) 2017-10-18
JP6236395B2 (ja) 2017-11-22
JP6549670B2 (ja) 2019-07-24
JP2018052947A (ja) 2018-04-05
US20140322151A1 (en) 2014-10-30
CN104302359B (zh) 2017-03-22
JP2014533667A (ja) 2014-12-15
DE102011119033A1 (de) 2012-09-06
EP2782645A2 (fr) 2014-10-01
CN104302359A (zh) 2015-01-21
BR112014012246A2 (pt) 2017-05-30
WO2013075826A3 (fr) 2014-02-20
EP3300771A1 (fr) 2018-04-04

Similar Documents

Publication Publication Date Title
EP3300771B1 (fr) Utilisation d'isosorbidecaprylates/caprates dans des déodorants et des anti-transpirants
DE69210515T2 (de) Kosmetisches Mittel
EP1915982A1 (fr) Utilisation du 1,2-décanediol pour réduire la concentration du sébum et/ou pour aider à la pénétration des actives dans des régions de la peau, et des compositions cosmétiques et/ou dermatologiques comprenant du 1,2-décanediol
EP1731036A1 (fr) Mélanges synergiques de 1,2-alcanediols
EP2739137B1 (fr) Utilisation des monoesters d'isosorbide comme agent epaississant
EP2739136A1 (fr) Utilisation de diesters d'isosorbide en tant qu'epaississants
WO2022069738A1 (fr) Composition pour traiter les cheveux, le cuir chevelu et la peau
EP0809483B1 (fr) Procede d'inhibition des brunissements induits par les sorbates dans les produits cosmetiques et alimentaires
DE2447627B2 (de) Antimikrobielles praeparat
WO2022069744A1 (fr) Composition pour le traitement des cheveux et du cuir chevelu
WO2022069742A1 (fr) Composition pour traiter les cheveux et la peau
EP4137119A1 (fr) Agent de soins capillaires comprenant un agent de conditionnement capillaire à base de triméthylglycine et d'un épaississant naturel
EP2934459A2 (fr) Protection améliorée contre l'odeur corporelle
WO2015022315A2 (fr) Préparations déodorantes et/ou antitranspirantes contenant des accepteurs de michaël polycycliques
WO2016102132A1 (fr) Utilisation d'octénidine comme principe actif déodorant
WO2019206489A1 (fr) Préparation à action anti-transpirante comprenant des sels de métal alcalino-terreux
EP3236920A1 (fr) Préparation antimicrobienne comprenant des alcanes de bispyridinium, des éthers de 1- ou 2-(c1 à c24-alkyl)-glycérol et des alcane-1,2-diols
DE10034137A1 (de) Wirkstoffkombinationen aus 3-Iodo-2-propinyl-butylcarbamat und einem oder mehreren 4-Hydroxybenzoesäureestern und Zubereitungen, solche Wirkstoffkombinationen enthaltend
WO2019219280A1 (fr) Préparation active antitranspirante sans eau
EP4137120A1 (fr) Apr?s shampoing comprenant un apr?s shampoing à base de triméthylglycine et d'une protéine ou d'un hydrolysat de protéine
WO2023194557A1 (fr) Composition pour le traitement de la peau
EP4137210A1 (fr) Agent de soins capillaires comprenant un agent conditionneur capillaire à base de triméthylglycine et un protéolipide
WO2020216696A1 (fr) Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate
EP4137118A1 (fr) Agent de traitement capillaire comprenant un agent de conditionnement capillaire à base de triméthylglycine et d'une huile
DE10034138A1 (de) Wirkstoffkombinationen aus 3-Iodo-2-propinyl-butylcarbomat und Phenoxyethanol und Zubereitungen, solche Wirkstoffkombinationen enthaltend

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2782645

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181004

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200115

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KLUG, PETER

Inventor name: MILDER,CARINA

Inventor name: FRICKE, TOM

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHALUPPA, CARINA

Inventor name: FRICKE, TOM

Inventor name: KLUG, PETER

AC Divisional application: reference to earlier application

Ref document number: 2782645

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502012016159

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1280592

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200918

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200917

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200917

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201019

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201017

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502012016159

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

26N No opposition filed

Effective date: 20210318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201121

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201121

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1280592

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201121

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20211126

Year of fee payment: 10

Ref country code: GB

Payment date: 20211123

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20220127

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502012016159

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221121

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130